Bayer AG shares surged higher on Tuesday this week on news that the German company forecast its peak sale of pharmaceuticals to €12 billion. Bayer forecast that its thrombosis treatment asundexian could bring in more than €5 billion. Revenue from the prostrate-cancer drug Nubeqa and cardio-renal therapy drug was set to both exceed €3 billion. Does this mean that Bayer can rely on these medicines as drivers for growth over the coming years?

Is a short-term run higher worth exploring for Bayer? The seasonal over the last 10 years have been promising seeing 8 gains in 10 years with an average return of 3%. The maximum gain has been a steady 12.27% in 2015 and the maximum loss has been a relatively modest -1.57%. So, is now the time to buy Bayer?

Major Trade Risks: The major trade risk here is bad news impacts on the wider stock market and that the prior seasonals do not guarantee the future years’ performance.

HYCM clients can access the Seasonax product in order to analyse over 25,000 currency pairs, indices, commodities, as well as individual stocks. Please contact your account manager for a free trial and get started right away. Certain products & services mentioned herein may or may not be available to all clients depending on which HYCM Capital Markets Group entity their trading account(s) adheres to.

HYCM Lab is a financial analysis source that provides regular insights on how global news affects the markets including forex, commodities, stocks, indices, and cryptocurrencies*. Run by the HYCM team, it equips traders with everything needed to make informed trading decisions.